Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Gastrointestinal tract motility regulation" does **not** refer to a single molecule, receptor, enzyme, or druggable target. Instead, it describes the complex physiological processes that coordinate muscular contractions and relaxations throughout the gastrointestinal tract to move contents from mouth to anus. This regulation involves multiple systems: - The **enteric nervous system**—including myenteric and submucosal plexuses—coordinates peristalsis and segmental contractions through excitatory and inhibitory neurons[1][3][6]. - **Neurotransmitters** such as acetylcholine (excitatory) and nitric oxide/vasoactive intestinal peptide (inhibitory) modulate smooth muscle activity. - **Interstitial cells of Cajal** act as pacemakers generating slow-wave electrical activity that coordinates rhythmic contraction patterns[1]. - **Hormones** like serotonin (5-hydroxytryptamine), motilin, secretin, somatostatin regulate various aspects of gut movement depending on feeding state or luminal stimuli[7]. - The **immune system**, particularly macrophages producing complement component C1q near enteric neurons, can influence neuronal gene expression affecting gut transit time[2]. - The **gut microbiota**, through microbial metabolites interacting with toll-like receptors TLR2/TLR4 on various cell types including smooth muscle cells and interstitial cells of Cajal, also modulates GI motility by influencing neurotrophic factors or inflammatory mediators[4]. Disorders arise when any part of this regulatory network malfunctions due to congenital defects (e.g., Hirschsprung disease), degenerative changes (e.g., achalasia), inflammation/infection/medication effects. Because "Gastrointestinal tract motility regulation" is not itself a discrete molecular entity but rather an integrated function involving many molecules/receptors/cells/systems working together—and because there are no standard abbreviations nor canonical forms for it—it should not be considered a valid therapeutic target entry under your requested conventions. For structured data purposes you should instead focus on individual components such as "Serotonin 5-hydroxytryptamine receptor 4", "Motilin receptor", "Toll-like receptor 4", etc.[1][4]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Gastrointestinal tract motility regulation.